프로티아

303360KOSDAQ의료용 기기 제조업

78.3 / 100

Reference Date: 2026-07-24

Financial Score30.0 / 40

News Sentiment21.3 / 25

Momentum17.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Surged 23.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

ProTia develops, manufactures, and sells in vitro diagnostic medical devices based on immune diagnostic technology, specializing in allergy, food intolerance, and antibiotic susceptibility tests. The company holds over 45% market share domestically and has expanded to 68 countries globally. It continuously innovates through its in-house research institute, earning three Yangsil Awards and four NET technology certifications from the government.

Number of Employees

113people

Average Salary

41.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

14.03Industry Average 20.046.5Point

Lower than industry avg (good)

PBR

2.04Industry Average 1.141.0Point

1.8x industry avg (risky)

ROE

15.72Industry Average 8.005.5Point

2.0x industry avg (good)

Debt Ratio

1.33Industry Average 11.658.0Point

Half of industry avg (excellent)

Trend 2023~20259.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲35.8% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲481.5% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 9.3% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Positive
프로티아, 2분기 영업이익률 32% 돌파...‘상반기 사상 최대 실적’
프로티아가 2분기 영업이익률을 사상 최대치로 달성하며, 매출과 이익이 크게 증가하고 프리미엄 제품의 성공적인 시장 진입으로 긍정적인 전망을 보임.

Detailed Momentum

52-week position5.0Point

52w mid range (40%)

Current 4,870Won52-week high 6,55052-week low 3,735

1-month return6.0Point

1m +23.92% (strong rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral영업(잠정)실적(공정공시)2026-07-15